Mersana Therapeutics Inc (MRSN)
3.57
+0.39
(+12.26%)
USD |
NASDAQ |
May 01, 15:02
Mersana Therapeutics Enterprise Value: 201.89M for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 30, 2024 | 201.89M |
| April 29, 2024 | 199.46M |
| April 26, 2024 | 172.78M |
| April 25, 2024 | 161.86M |
| April 24, 2024 | 165.50M |
| April 23, 2024 | 205.53M |
| April 22, 2024 | 198.25M |
| April 19, 2024 | 210.38M |
| April 18, 2024 | 221.30M |
| April 17, 2024 | 243.13M |
| April 16, 2024 | 272.25M |
| April 15, 2024 | 275.89M |
| April 12, 2024 | 278.31M |
| April 11, 2024 | 267.39M |
| April 10, 2024 | 265.57M |
| April 09, 2024 | 313.49M |
| April 08, 2024 | 320.77M |
| April 05, 2024 | 335.32M |
| April 04, 2024 | 331.68M |
| April 03, 2024 | 355.95M |
| April 02, 2024 | 328.05M |
| April 01, 2024 | 352.31M |
| March 28, 2024 | 359.58M |
| March 27, 2024 | 360.80M |
| March 26, 2024 | 337.75M |
| Date | Value |
|---|---|
| March 25, 2024 | 334.11M |
| March 22, 2024 | 386.27M |
| March 21, 2024 | 399.61M |
| March 20, 2024 | 403.25M |
| March 19, 2024 | 417.81M |
| March 18, 2024 | 405.68M |
| March 15, 2024 | 427.51M |
| March 14, 2024 | 423.27M |
| March 13, 2024 | 512.43M |
| March 12, 2024 | 500.30M |
| March 11, 2024 | 506.36M |
| March 08, 2024 | 517.28M |
| March 07, 2024 | 525.77M |
| March 06, 2024 | 512.43M |
| March 05, 2024 | 516.07M |
| March 04, 2024 | 513.64M |
| March 01, 2024 | 536.69M |
| February 29, 2024 | 476.04M |
| February 28, 2024 | 404.47M |
| February 27, 2024 | 334.11M |
| February 26, 2024 | 308.64M |
| February 23, 2024 | 275.89M |
| February 22, 2024 | 272.44M |
| February 21, 2024 | 261.57M |
| February 20, 2024 | 254.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-133.82M
Minimum
Aug 02 2023
1.624B
Maximum
Dec 23 2020
431.61M
Average
316.67M
Median
Mar 02 2020
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 3.051B |
| Geron Corp | 1.892B |
| TG Therapeutics Inc | 1.992B |
| Editas Medicine Inc | 103.55M |
| G1 Therapeutics Inc | 166.19M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.54M |
| Revenue (Quarterly) | 10.70M |
| Total Expenses (Quarterly) | 31.63M |
| EPS Diluted (Quarterly) | -0.16 |
| Profit Margin (Quarterly) | -182.6% |
| Earnings Yield | -42.02% |
| Normalized Earnings Yield | -39.99 |